Jiajun Liu
About
In The Last Decade
Jiajun Liu
58 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 113
- Molecular Biology 390
- Rheumatology 341
- Immunology 224
- Biomedical Engineering 207
- Oncology 171
Countries citing papers authored by Jiajun Liu
This map shows the geographic impact of Jiajun Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiajun Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiajun Liu more than expected).
Fields of papers citing papers by Jiajun Liu
This network shows the impact of papers produced by Jiajun Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiajun Liu. The network helps show where Jiajun Liu may publish in the future.
Co-authorship network of co-authors of Jiajun Liu
This figure shows the co-authorship network connecting the top 25 collaborators of Jiajun Liu. A scholar is included among the top collaborators of Jiajun Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiajun Liu. Jiajun Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 1 | |
| 4 | 3 | |
| 5 | 4 | |
| 6 | 1 | |
| 7 | 2 | |
| 8 | 3 | |
| 9 | 4 | |
| 10 | 2 | |
| 11 | 79 | |
| 12 | 17 | |
| 13 | 8 | |
| 14 | 167 | |
| 15 | 24 | |
| 16 | 10 | |
| 17 | Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study breakdown → | 301 |
| 18 | 108 | |
| 19 | [Construction of genetically modified dendritic cell vaccine expressing bcr/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro]. | 1 |
| 20 | 16 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.